Drug Approval | May 14, 2022
Zydus launches Bemdac to treat LDL-Cholesterol
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Subscribe To Our Newsletter & Stay Updated
